MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial. The new data ...
MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to be worth more than $3 billion – according to media reports. The Financial ...
Windows Update has improved dramatically over the past few years and is getting better. The Windows Team is now making it easier for consumers and businesses to locate the driver and optional updates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback